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ype 2 diabetes is a leading cause of morbidity
and mortality worldwide (1). In the last 15 years,
the number of people in the U.S. with diagnosed
diabetes has more than doubled. Strong risk
factors for type 2 diabetes include age, sex, obesity,
physical inactivity, and family history (2). Several mea-
sured genetic variants have recently emerged as risk
factors for type 2 diabetes. In this commentary, we discuss
the impact of new gene discoveries on prediction and
prevention of type 2 diabetes. We propose that the new
multidisciplinary ﬁeld of public health genomics can help
translate gene discoveries into appropriate actions to
reduce the burden of type 2 diabetes in the population.
Role of genetic factors in type 2 diabetes. It has long
been recognized that type 2 diabetes runs in families even
though only a few diabetes-related genetic diseases have
been identiﬁed (3). Until recently, the quest for genetic
susceptibility to type 2 diabetes has frustrated research-
ers. Since the completion of the Human Genome Project in
2003 (4), and the Haplotype Mapping (HapMap) Project in
2005 (5), the stage was set for using large-scale collabora-
tive genome-wide association studies (GWAS) to search
for genetic factors for many common diseases of public
health importance, including type 2 diabetes (6). Since
2007, the scientiﬁc community has begun to reap the
beneﬁts of GWAS, with 170 studies published and many
replicated genetic “hits” found across the genome for a
variety of common diseases. These ﬁndings fuel expecta-
tions that genetic factors can be used to construct suscep-
tibility proﬁles that will help in the prediction, prevention,
and early detection of human diseases, thus ushering in a
new era of personalized health care and disease preven-
tion (7).
Current ﬁndings on the genetics of type 2 diabetes. In
this issue, van Hoek et al. (8) and Lango et al. (9) take
GWAS ﬁndings in type 2 diabetes to the next logical level
by asking the question of whether genetic risk factors for
type 2 diabetes discovered using GWAS can be combined
to improve the prediction of risk of type 2 diabetes among
adults. van Hoek et al. genotyped 18 genetic variants from
recent GWAS on type 2 diabetes in a prospective popula-
tion-based study among almost 6,544 individuals 55
years of age. Lango et al. assessed 18 variants in 2,598
control subjects and 2,309 case subjects from a popula-
tion-based study of individuals of white European descent
living in the Tayside region in the U.K. There was consid-
erable overlap between the set of genes in the two studies.
Despite different study designs, methods, and case deﬁni-
tions, the two studies essentially showed similar ﬁndings.
van Hoek et al. found that when genetic variants are
combined together to predict the incidence of type 2
diabetes, they had only weak predictive ability in their
population. The area under the curve, a measure of
discriminative accuracy, was 0.60 for prediction based on
the genetic polymorphisms; 0.66 for age, sex, and BMI; and
0.68 for the genetic polymorphisms and clinical character-
istics combined. Lango et al. also found that individuals
carrying more risk alleles had higher risk of type 2
diabetes. However, the area under the curve for these
variants was 0.60. The area under the curve for age, BMI,
and sex was 0.78, and adding the genetic risk variants only
marginally increased this to 0.80.
Both studies have strengths and limitations, as acknowl-
edged by the investigators. These include the relatively
small sample sizes; the lack of the prospective nature of
the Lango study; the various ethnic groups and the poten-
tial lack of generalizability of ﬁndings; the lack of power to
examine interactions; the potential that genetic effects
could be mediated through other measured risk factors
such as BMI leading to possible collinearity; and the fact
that these genetic markers may not be the true causal
variants in type 2 diabetes (with misclassiﬁcation due to
linkage disequilibrium and weakening of effect sizes). An
additional methodological issue is the lack of a compara-
ble and standardized case deﬁnition of the type 2 diabetes
phenotype between the two studies. Lastly, neither study
considered family history for type 2 diabetes, which is
likely a strong and independent risk factor (reﬂecting both
genetic and environmental factors).
Can genetic factors be used to predict the risk of type
2 diabetes? The results of these two studies clearly
indicate that currently we have a limited ability to predict
the risk of type 2 diabetes in the general population based
on genetic proﬁles, especially when added to established
risk factors. This ﬁnding also is consistent with recent
ﬁndings on genetic factors from other common diseases
such as prostate cancer (10) and coronary heart disease
(11). Clearly, our ability to predict type 2 diabetes using
genetic risk factors is likely to improve as more variants
are discovered, especially if these variants have stronger
effect sizes than the current ones (most current ones have
odds ratios under 2), if strong gene-gene and gene-
environment interactions are found, or if biochemical or
physiological biomarkers that are more proximal to the
development of type 2 diabetes are discovered and vali-
dated. Nevertheless, GWAS ﬁndings have great implications
in terms of understanding disease biology and pathogenesis
and the future development of preventive and treatment
interventions.
The public health genomics approach to type 2 dia-
betes. So, while exciting gene discoveries are being made,
what can we do? The answer may lie in the relatively new
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concerned with the effective and responsible translation of
genome-based knowledge and technologies to improve
population health” (12). Researchers, policymakers, and
practitioners in public health genomics use population-
based data on genetic variation and gene-environment
interactions to develop, implement, and evaluate evidence-
based tools for improving health and preventing disease.
They also apply systematic evidence-based knowledge
synthesis and appraisal of the clinical validity and utility of
genomic applications in health practice. Validated
genomic information is then integrated into disease con-
trol and prevention programs (13).
Like many areas of public health, public health genom-
ics uses translation phases to progress from discovery to
population health impact (14). Because multiple disci-
plines participate, the process encourages feedback loops
and ongoing knowledge synthesis and dissemination. Al-
though many translation schemas are available, we show
in Fig. 1a continuum adapted from Khoury et al. for type 2
diabetes. Phase one (T1) research seeks to move a basic
genomic discovery into a candidate health application
(e.g., promising genetic test/intervention). Phase two (T2)
research assesses the value of a genomic application for
health practice leading to the development of evidence-
based guidelines. Phase three (T3) research attempts to
move evidence-based guidelines into health practice
through knowledge transfer, delivery, dissemination, and
diffusion research. Phase four (T4) research and evalua-
tion seek to assess the “real world” health outcomes of a
genomic application in practice. Because the development
of evidence-based guidelines is a moving target, multiple
disciplines are involved in translation research and pro-
vide feedback loops to allow integration of new knowl-
edge into practice. Table 1 lists examples of translation
genomics research activities related to type 2 diabetes.
The two articles published in this issue are examples of T1
research. Most current human genomics research is dis-
covery based. We have recently estimated that no more
than 3% of published human genomics studies focus on T2
and beyond (14). Indeed, evidence-based guidelines and
T3 and T4 research in genomics currently are rare (except
in newborn screening programs for rare metabolic disor-
ders). At present, there are no evidence-based recommen-
dations for the use of genomics in the prevention or
treatment of type 2 diabetes.
Knowledge synthesis and dissemination to providers,
consumers, and policymakers is at the core of the public
health genomics enterprise (Fig. 1). Because of the rapidly
emerging information on the genetics of common disease,
such as the information reported in the two articles, we
need authoritative and credible processes to rapidly sum-
marize what we know and what we don’t know about the
role of genetic factors in human diseases and to determine
whether or not the use of such information is likely to lead
to health beneﬁt at the individual and population levels.
The Centers for Disease Control and Prevention has
developed two knowledge synthesis initiatives in genom-
ics. The ﬁrst is the Human Genome Epidemiology Network
(HuGENet), which is a global collaboration of individuals
and networks interested in developing the knowledge base
on genes and diseases (15). An online, searchable, and
continuously updated database is available (16). As of 1
August 2008, 431 genes have been studied in relation to
type 2 diabetes with more than 1,340 publications and 50
meta-analyses as well as 15 GWAS.
FIG. 1. A public health genomics framework for translating human genetic discoveries into diabetes control and prevention. Diagram modiﬁed
from Khoury et al. (14)
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uation of Genomic Applications in Practice and Prevention
(EGAPP) initiative (17). This is an independent multidis-
ciplinary expert panel that commissions evidence-based
reviews of the clinical validity and utility of genetic tests in
speciﬁc clinical and population health scenarios. The
EGAPP working group is developing evidence-based clin-
ical guidelines for a variety of diseases. The ﬁrst such
guideline was published on the use of cypP450 genetic
polymorphism in the treatment of depression with antide-
pressive medications (18). Currently, the EGAPP working
group is evaluating emerging tests with multiple variants
that purport to predict future risk of type 2 diabetes
(similar to what the authors of the two articles were trying
to assess). Details on EGAPP methodology are published
elsewhere (19).
Concluding remarks. Can genetic risk factors be used for
the prediction of type 2 diabetes? The answer is not yet. It
is certainly possible that as the discoveries of genetic
factors continue at a rapid pace, we may have enough
variants that, when combined with other risk factors and
clinical variables, may lead to more predictive risk pro-
ﬁles. Even then, we need to ﬁgure out how such informa-
tion can be communicated and whether or not it will affect
the adoption of healthy lifestyles and the seeking of
medical interventions that could lead to overall reduction
in type 2 diabetes burden. This is a long process involving
different ﬁelds of clinical and population studies, both
observational studies and clinical trials. In the meantime, in
spite of our incomplete knowledge of the genetics of type 2
diabetes today, the burden of type 2 diabetes can be amelio-
rated at the population level. Recent studies have found that
lifestyle changes through diet and exercise can prevent or
delay the onset of type 2 diabetes. For people already
living with diabetes, much of this burden could be pre-
vented with early detection, improved delivery of care, and
adequate management (1). Concerted clinical and public
health efforts are underway to assist in reducing the
burden of diabetes in the population. In addition, a simple
tool such as family history of type 2 diabetes can raise the
level of awareness about the role of shared genes and
environments in families and the need for risk-reducing
behaviors. In the ﬁnal analysis, traditional risk factors,
including family history (20), still provide the most reliable
approach to deﬁning different levels of risk for developing
type 2 diabetes in the population.
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